Therefore, IVIg therapy could be a potential therapeutic option against COVID-19 [59]. the end of 2019, the National Health Commission of China released more details about the epidemic in early 2020 [2]. The causative computer virus was initially RO-9187 called novel coronavirus 2019 (2019-nCoV) by the World Health Business (WHO), but it was then renamed as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the international committee of the Coronavirus Study Group (CSG), and the disease called coronavirus disease 2019 (COVID-19) by WHO [3]. It is thought that the Hunan seafood market in Wuhan city in China was the origin of the outbreak. Although it had been proposed that this COVID-19 patients in China might have utilized infected animals as a foodstuff, or might have frequented the seafood market, further investigation revealed that some patients had not frequented the seafood market. Snap23 Therefore, the human-to-human transmission of this virus through coughing, sneezing, and the spread of respiratory droplets or aerosols was accepted. Additionally, almost all countries in continents throughout the world reported disease spread caused by aerosol penetration into the upper the respiratory tract and lungs via inhalation [4], [5]. There followed a rapid growth in the number of cases all around the world. A mathematical model examined whether the control of SARS-CoV-2 contamination could be achieved by isolating affected patients, and tracking their contacts with other individuals. This model concluded that isolating people and critiquing their contacts would be insufficient to control the COVID-19 pandemic within three months, because there would be too much delay between the onset of symptoms and isolation [6]. Thus, observing preventive measures, especially isolation and lockdown, would be essential. SARS-CoV-2 is highly contagious, and there has not yet been any vaccine or effective treatment that has received approval. So, the best answer for controlling the pandemic will be the simultaneous application of preventive methods, sensitive diagnostic methods, and using current available drugs, while still developing novel treatments [7], [8], [9]. This study presents the latest information about COVID-19 transmission, prevention, and potential therapeutic options. 2.?SARS-CoV-2 characteristics SARS-CoV-2 is an enveloped, positive-sense, and single-stranded 29.9?kb RNA beta-coronavirus [10], [11]. Investigation of the SARS-CoV-2 genome proved that it has 88% similarity with the RO-9187 bat-SL-CoVZC45 and bat-SL-CoVZXC21 sequences, and was 96.2% identical to another bat CoV RaTG13 [12]. However, some recent investigations have suggested that pangolins that were smuggled from Malaysia to China, along with other possible intermediate hosts like turtles or snakes could be the direct origin of the virus instead of a bat [13]. Moreover, the protein-coding genes of SARS-CoV-2 have 79.5% and 51% sequence similarity to SARS-CoV and MERS-CoV, respectively. The SARS-CoV-2 computer virus employs the Angiotensin-Converting Enzyme 2 (ACE2) receptor for cellular entry, much like SARS-CoV [3], [14]. Therefore, previous treatments that were used to control the SARS-CoV and MERS-CoV epidemics, might also be effective in SARS-CoV-2. 3.?Clinical consequences The first symptoms are commonly recognized as fever, dry cough, tachypnea, and shortness of breath [15]. Although diarrhea was present in about 20C25% of patients with MERS-CoV or SARS-CoV contamination, intestinal symptoms are rarely seen in patients with COVID-19. In another study, confusion, chest pain, vomiting, and nausea were also reported as COVID-19 symptoms [16]. Other symptoms include, sore throat, sneezing, nasal congestion, sputum production, anosmia and dyspepsia, rash on the skin, or discoloration of fingers or toes, and viral conjunctivitis. Some laboratory studies have shown the occurrence of cytokine storm, sepsis, and RNAaemia in COVID-19 [17], [18]. Clinical chemistry studies have shown increases in lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine transaminase (ALT), C-reactive RO-9187 protein (CRP), creatine kinase (CK), erythrocyte sedimentation rate (ESR), white blood cell (WBC) count, D-dimer level, procalcitonin, urea, and creatinine. Decreases in hemoglobin, lymphocyte count, eosinophil count, and serum albumin have been detected in COVID-19 patients [17]. The most common radiological findings in patients with COVID-19 were a ground-glass opacity in the lungs [19]. Moreover, SARS-CoV-2 can affect the cardiovascular system [16], gastrointestinal tract [20], and can cause acute kidney failure [2], [19]. Moreover, evaluation of liver manifestations in 148 patients with COVID-19 indicated that more than one-third of the COVID-19 patients admitted to the hospital had abnormal liver function, and these patients were hospitalized for a more extended RO-9187 period [21]. It must be mentioned that it is likely that a substantial quantity of asymptomatic patients can be service providers of the computer virus. The variable clinical manifestations and outcomes underline the importance of adhering.
Categories
- 11??-Hydroxysteroid Dehydrogenase
- 45
- 5-HT6 Receptors
- 7-TM Receptors
- 7-Transmembrane Receptors
- Acetylcholine Nicotinic Receptors, Non-selective
- Adrenergic ??1 Receptors
- Adrenergic Related Compounds
- AHR
- Aldosterone Receptors
- Androgen Receptors
- Antiprion
- AT2 Receptors
- ATPases/GTPases
- Atrial Natriuretic Peptide Receptors
- Calcineurin
- CAR
- Carboxypeptidase
- Casein Kinase 1
- Corticotropin-Releasing Factor
- CysLT1 Receptors
- Dardarin
- Deaminases
- Death Domain Receptor-Associated Adaptor Kinase
- Delta Opioid Receptors
- DMTs
- DNA-Dependent Protein Kinase
- Dual-Specificity Phosphatase
- Dynamin
- eNOS
- ER
- G Proteins (Small)
- GAL Receptors
- General
- GLT-1
- Glucagon and Related Receptors
- Glycine Receptors
- Growth Factor Receptors
- Growth Hormone Secretagog Receptor 1a
- GTPase
- Guanylyl Cyclase
- KDM
- Kinesin
- Lipid Metabolism
- Main
- MAPK
- MCH Receptors
- Muscarinic (M2) Receptors
- NaV Channels
- Neurotransmitter Transporters
- NFE2L2
- Nitric Oxide Precursors
- Nitric Oxide Signaling
- NPFF Receptors
- Opioid
- Other
- Other MAPK
- Other Peptide Receptors
- Other Transferases
- OX1 Receptors
- OX2 Receptors
- OXE Receptors
- PAO
- Phosphatases
- Phosphoinositide 3-Kinase
- Phosphorylases
- Pim Kinase
- Polymerases
- Purine Transporters
- Sec7
- Serine Protease
- Sodium/Calcium Exchanger
- Sphingosine Kinase
- V2 Receptors
-
Recent Posts
- Range bar = 100 m
- Sad to say, a specific gun or pair of markers with CSCs in neuroblastoma is actually not established
- The symptoms happened 48hprior to medical talking to
- One report suggested that RTA could be transient in pregnant patients and that they recovered after delivery [6]
- Tissues samples meant for the study in to primary open up angle glaucoma were acquired after enucleation of a glaucoma case by a veterinary ophthalmologist on well being grounds because of the severity of clinical indications (carried out in accordance together with the Veterinary Cosmetic surgeons Act 1966 and underneath the auspices with the RCVS)
Tags
- 68521-88-0
- a 105-120 kDa heavily O-glycosylated transmembrane glycoprotein expressed on hematopoietic progenitor cells
- Ankrd11
- Capn1
- Carboplatin cost
- DKFZp781B0869
- HA6116
- Hdac11
- IGF2R
- INK 128 supplier
- JTK4
- LRP2
- Masitinib manufacturer
- MDA1
- Mouse monoclonal to CD34.D34 reacts with CD34 molecule
- Mouse monoclonal to ERBB3
- Mouse monoclonal to INHA
- order NVP-AEW541
- PECAM1
- Rabbit Polyclonal to AML1
- Rabbit polyclonal to AML1.Core binding factor CBF) is a heterodimeric transcription factor that binds to the core element of many enhancers and promoters.
- Rabbit Polyclonal to AQP12
- Rabbit Polyclonal to C-RAF phospho-Ser301)
- Rabbit Polyclonal to C-RAF phospho-Thr269)
- Rabbit polyclonal to CD80
- Rabbit Polyclonal to Claudin 3 phospho-Tyr219)
- Rabbit Polyclonal to CYSLTR1
- Rabbit polyclonal to DDX20
- Rabbit Polyclonal to EDG4
- Rabbit Polyclonal to FGFR2
- Rabbit Polyclonal to GAS1
- Rabbit Polyclonal to GRP94
- Rabbit polyclonal to INMT
- Rabbit Polyclonal to KAPCB
- Rabbit Polyclonal to MMP-2
- Rabbit Polyclonal to MT-ND5
- Rabbit Polyclonal to OR52E2
- Rabbit polyclonal to PHC2
- Rabbit Polyclonal to RAB31
- Rabbit Polyclonal to SLC25A31
- Rabbit Polyclonal to ZC3H13
- Rabbit polyclonal to ZNF268
- TNFRSF13C
- VAV1
- Vegfa